Shares of ADMA Biologics Inc (NASDAQ:ADMA) have earned an average broker rating score of 1.33 (Strong Buy) from the three analysts that provide coverage for the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a buy rating and two have issued a strong buy rating on the company. ADMA Biologics’ rating score has improved by 20.4% in the last three months as a result of a number of analysts’ upgrades and downgrades.

Analysts have set a 12-month consensus price target of $7.63 for the company and are expecting that the company will post ($0.51) EPS for the current quarter, according to Zacks. Zacks has also assigned ADMA Biologics an industry rank of 115 out of 265 based on the ratings given to its competitors.

A number of analysts recently issued reports on the company. ValuEngine cut ADMA Biologics from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st. Maxim Group reissued a “buy” rating and set a $8.00 price objective (down previously from $13.00) on shares of ADMA Biologics in a report on Monday, December 11th. Finally, Raymond James Financial raised ADMA Biologics from a “market perform” rating to an “outperform” rating and set a $5.00 price objective on the stock in a report on Tuesday, November 14th.

ADMA Biologics (NASDAQ ADMA) opened at $2.59 on Thursday. ADMA Biologics has a 1 year low of $2.01 and a 1 year high of $5.79. The company has a current ratio of 2.36, a quick ratio of 1.35 and a debt-to-equity ratio of 2.26.

In related news, Director Eric I. Richman acquired 25,000 shares of the company’s stock in a transaction that occurred on Thursday, November 9th. The shares were acquired at an average price of $2.15 per share, with a total value of $53,750.00. Following the acquisition, the director now owns 31,300 shares of the company’s stock, valued at approximately $67,295. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Adam S. Grossman acquired 485,000 shares of the company’s stock in a transaction that occurred on Thursday, November 9th. The shares were bought at an average cost of $2.15 per share, for a total transaction of $1,042,750.00. The disclosure for this purchase can be found here. Insiders have purchased a total of 526,500 shares of company stock worth $1,131,975 in the last three months. 60.44% of the stock is currently owned by insiders.

A hedge fund recently raised its stake in ADMA Biologics stock. Iguana Healthcare Management LLC boosted its holdings in ADMA Biologics Inc (NASDAQ:ADMA) by 276.7% during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 565,000 shares of the biotechnology company’s stock after acquiring an additional 415,000 shares during the quarter. Iguana Healthcare Management LLC owned 2.19% of ADMA Biologics worth $1,740,000 at the end of the most recent reporting period. 32.78% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: “Analysts Anticipate ADMA Biologics Inc (ADMA) to Announce ($0.51) EPS” was reported by Watch List News and is owned by of Watch List News. If you are reading this news story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this news story can be read at

About ADMA Biologics

ADMA Biologics, Inc is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics.

Get a free copy of the Zacks research report on ADMA Biologics (ADMA)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with's FREE daily email newsletter.